feedback

Course Director

Bruce Cree, MD, PhD, MAS
Bruce Cree, MD, PhD, MAS

UCSF Multiple Sclerosis Center
San Francisco, California

Faculty

Anne Haney Cross
Anne Haney Cross, MD

Washington University School of Medicine
St. Louis, Missouri

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CE / CPE
Credit Amount:1.5 Credits
Release Date:2018-Jun-29
Expiration Date:2019-Jun-28
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

The discovery that subtype 1 of the sphingosine-1-phosphate receptor (S1PR1) is expressed on the surface of lymphocytes and is important in regulating egression from lymph nodes led to the development and approval of the S1PR modulator fingolimod for the treatment of multiple sclerosis (MS). Although fingolimod remains an attractive treatment because of its efficacy, tolerability, and convenient oral dosing, the use of this agent has been limited in certain populations because of undesirable effects (ie, bradycardia, macular edema) due to its interaction with other S1PR subtypes expressed in diverse tissues. Consequently, agents that more selectively target S1PR1 have been highly sought after for the treatment of MS; a number of these agents are in the later stages of clinical development. The advent of second-generation S1PR modulators with greater specificity for S1PR1 will likely expand the population of patients with MS who can benefit from this class of medication.

In this unique activity, based on a recent live satellite symposium held in conjunction with the 2018 Annual Meeting of the CMSC, important insights are offered into the class of S1PR modulators for the treatment of MS. Key similarities and differences among the S1PR modulators are explored, along with the latest data on these therapies and exciting potential clinical benefits associated with newer agents.

Upon completion of this activity, participants will be able to:
  • Recognize the biological processes regulated by sphingosine-1-phosphate and its receptor
  • Differentiate between approved and emerging sphingosine-1-phosphate receptor modulators according to their selectivity for receptor subtypes
  • Apply available data on established and investigational sphingosine-1-phosphate receptor modulators when managing patients with multiple sclerosis
  • Assess the potential clinical implications of the increased selectivity of emerging sphingosine-1-phosphate receptor modulators on patient safety

Target Audience

This activity has been designed to meet the educational needs of neurologists; nurse practitioners, physician assistants, and nurses in the neurology setting; pharmacists; and other clinicians involved in the management of multiple sclerosis.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge of nurses concerning the treatment of multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 29, 2018 - June 28, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CE/CPE activity during the past 12 months.

Course Director

Bruce Cree, MD, PhD, MAS
Associate Professor of Neurology
Director, Clinical Research
UCSF Multiple Sclerosis Center
San Francisco, California

Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Biogen; EMD Serono, Inc.; GeNeuro SA; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC/Genzyme Corporation.
Advisory Board for Akili.
Bruce Cree, MD, PhD, MAS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: sphingosine-1-phosphate receptor modulators that are currently under investigation for the treatment of MS.

Faculty

Anne Haney Cross, MD
Professor of Neurology and Head of the Neuroimmunology Section
Washington University School of Medicine
St. Louis, Missouri

Anne Haney Cross, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC/Genzyme Corporation.
Grant/Research Support from Genentech, Inc. (as part of multicenter trial).
Anne Haney Cross, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: sphingosine-1-phosphate receptor modulators that are currently under investigation for the treatment of MS.

CME Reviewers

Randy Rosenberg, MD, FAAN, FACP

Randy Rosenberg, MD, FAAN, FACP, has no financial interests/relationships or affiliations in relation to this activity.

Kaushal Patel, MD

Kaushal Patel, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Bobbie Perrin, RN, OCN

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer

Shelley Chun, PharmD

Shelley Chun, PharmD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME’s Program Reporting and Activity System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hour(s).

Pharmacists

ACPEThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-18-006-H01-P.

Providership

This CME/MOC/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CE/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.